-Ends-
Oxford, UK – 3 December, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, is pleased to announce that, John Dawson, Chief Executive Officer of Oxford Biomedica, was named Executive of the Year in the category for Companies with a market cap <$10 billion at the 16th Annual Scrip Awards 2020.
This award recognises Oxford Biomedica’s achievements from June 2019 up to the end of May 2020, taking into account the Company’s efforts on the Lentivector® platform and subsequent partnership agreements, which more than doubled in the period from nine to nineteen, including a deal with Juno Therapeutics, a Bristol-Myers Squibb company, the extension of the commercial supply agreement with Novartis for a further five years to work on six programmes, and R&D collaboration with Santen to develop gene therapy products inherited retinal disease.
John Dawson, Chief Executive Officer of Oxford Biomedica, said: “It is a huge honour to accept this award on behalf of everyone at Oxford Biomedica and this is a true testament to the dedication and hard work demonstrated by everyone at the Company. We’ve collectively won this award for our efforts on our Lentivector® platform and deals including Juno Therapeutics, a Bristol-Myers Squibb company, and the Novartis extension. This award is by far the biggest recognition that Oxford Biomedica has received for its achievements in driving gene therapy forward for patients, and as a leader in the space. Congratulations to the other nominees on their work this year, and thank you to Scrip for recognising Oxford Biomedica.”
Enquiries:
Oxford Biomedica plc
John Dawson, Chief Executive Officer, T: +44 (0)1865 783 000
Stuart Paynter, Chief Financial Officer, T: +44 (0)1865 783 000
Catherine Isted, Head of Corporate Development & IR, T: +44 (0)1865 954 161 / E: ir@oxb.com
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal, T: +44 (0)20 3709 5700
About Oxford Biomedica
Oxford Biomedica (LSE:Oxford Biomedica) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a 3 year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people. Further information is available at www.oxb.com